Brief: Algernon Pharmaceuticals Submits U.S. FDA Pre-Ind Meeting Request For Psychedelic Drug Dmt Clinical Research Program For Stroke
17/03/2021 11:45
March 17 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS INC - SUBMITS U.S. FDA PRE-IND
MEETING
REQUEST FOR PSYCHEDELIC DRUG DMT CLINICAL RESEARCH PROGRAM FOR
STROKE
Source text for Eikon: ID:nGNX2GK2XB
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement